110 likes | 193 Vues
This draft working paper discusses financing mechanisms for health research and development, exploring options to increase funding for diseases disproportionately affecting developing countries. Criteria for assessing mechanisms are presented, along with existing mechanisms in the health research field. The goal is to identify research gaps, set priorities, and establish a new voluntary funding mechanism that considers IP management. Contact Dr. Peter Beyer for more information.
E N D
PPPs Norm-setting and Policy Challenges What role for PDPs in a future framework for neglected disease research? ICTSD, Geneva, June 2013 Dr Peter Beyer
World Health Assembly 2013 WHA66.22 inter alia REQUESTS the Director-General (6) to explore and evaluate existing mechanisms for contributions to health R&D and, if there is no suitable mechanism, to develop a proposal for effective mechanisms, including pooling resources and voluntary contributions, as well as a plan to monitor their effectiveness independently (8) to report on […] the evaluation of existing mechanisms for contributions to health R&D […] to the 67th World Health Assembly, through the Executive Board at its 134th session; […]
DRAFT WORKING PAPER 3FINANCING MECHANISMS FOR HEALTH R&D Draft working paper • Explores option of adapting an existing instrument to increase funding of R&D for diseases disproportionately affecting developing countries (pooling funding) • identifies a number of mechanisms that could be suitable starting points and • presents criteria that could be used to assess suitability of a range of existing mechanisms.
Existing mechanisms in the area of health • ANDI • DNDi • EMBL • GAVI Alliance • Global Fund • IARC • IVI • MMV • PATH • RBM • WHO/TDR • UNITAID
Assessment criteria • Adaptability: can the mechanism easily be adapted to take up the global funding of health R&D • Scope of research: Which disease areas and technologies are covered? • Geographical scope: if and to what extent the mechanism is geographically limited • Governance: is the governing structure inclusive? • Experience in funding R&D • Experience in managing R&D • Transparency: are the criteria used to distribute funding and the minutes of governing body meetings publicly available?
Where are we heading? Ideally in the end (if Member States so agree): • Research gaps will be identified by the health R&D observatory • Based on this data research priorities will be identified in conjunction with a new voluntary funding mechanism • New voluntary funding mechanism Impact on IP management (by PDPs)? Funding will be linked with certain requirements/principles for accessibility and availability, including IP management
Contact Dr Peter BeyerSenior Advisor, WHO Department of Public Health, Innovation and Intellectual Property http://www.who.int/phi/en/beyerp@who.int .